Betahistine intranasal - Auris Medical

Drug Profile

Betahistine intranasal - Auris Medical

Alternative Names: AM-125; AM-201 - Auris Medical

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Melbourne
  • Developer Auris Medical; Otifex Therapeutics
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Meniere's disease; Vertigo
  • Research Weight gain
  • Discontinued Otitis

Most Recent Events

  • 03 Jul 2018 Pharmacodynamics data from a preclinical study released by Auris Medical
  • 15 May 2018 Early research in Weight gain in Switzerland (Intranasal)
  • 15 May 2018 Auris Medical has patent protection for betahistine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top